Αρχική World News FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative... World News FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer Από Ogkologos - 9 Σεπτεμβρίου, 2026 164 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study 1 of the VIKTORIA-1 Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced... 19 Ιουλίου, 2024 ΠΟΝΟΣ 8 Μαρτίου, 2019 Life-saving scheme to improve cancer screening among Muslim women 20 Ιουλίου, 2023 ESMO Welcomes European Parliament (EP) Draft Report on Psychosocial Risks at... 2 Απριλίου, 2026 Φόρτωση περισσοτέρων HOT NEWS New on NCI’s Websites for March 2022 FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma EMA Recommends Granting Marketing Authorisation for Generic Abiraterone Acetate EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim